echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Pharmaceutical Marketing > National organization coronary stent centralized procurement continued procurement started A number of highlights attracted attention

    National organization coronary stent centralized procurement continued procurement started A number of highlights attracted attention

    • Last Update: 2023-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Coronary stent is the first variety in China to carry out the centralized procurement of national high-value medical consumables, and the first procurement cycle is about to expire
    .
    Today (November 29), the National Joint Procurement Office for High-value Medical Consumables carried out the continuation of the next cycle of centralized procurement of coronary stents in Changzhou
    , Jiangsu Province.
     
    At 9 a.
    m.
    , the declaring enterprise began to submit the declaration materials, and after the notary public reviewed, the meeting staff announced the enterprise declaration information
    .
    A total of 3,696 medical institutions participated in the procurement declaration after the expiration of the national organization coronary stent volume procurement agreement, an increase of 1,288 compared with the first centralized procurement, and a total of 1.
    865 million
    medical institutions filled in the demand.
     
    Hu Jun, representative of a foreign-funded enterprise: Because as a foreign-funded enterprise, the Chinese market is very important
    .
    After the procurement with quantity, I think it should be a very good result
    for enterprises, governments, and people.
     
    The coronary stent continuation extended the procurement cycle from the previous 2 years to 3 years, which on the one hand reduced the frequency of re-docking work and saved administrative costs; On the other hand, it guides enterprises to form long-term stable expectations, ensures the stability of the market pattern in a longer period of time, and promotes enterprises to invest part of their time and energy in R&D and innovation
    .
     
    This successive purchase, there are also many optimizations
    in the rules.
    For example, enterprise products that have not won the bid before and new products approved in the past two years can also participate in it, giving enterprises sufficient opportunities to compete
    through volume-price linkage and volume-for-price.
     
    This successive procurement simplifies the procurement rules, stipulates that the quotation is not higher than the highest effective declared price to obtain the qualification to be selected, and the enterprise can obtain the qualification
    to be selected to the greatest extent.
    Previously unselected products and new products can participate in collective procurement as long as they accept the highest effective declared price, giving unselected products full opportunities, alleviating the dilemma that newly approved products cannot catch up with national procurement, and promoting the development
    of clinical use to a higher technical level.
     
    At the same time, through gradient allocation of agreed procurement volume, promote full competition of enterprises, give full play to the effect of centralized procurement "volume price linkage, volume for price", and guide enterprises to reasonably reduce prices to obtain more agreed procurement volume
    .
     
    Gu Hai, director of the Health Policy and Management Research Center of Nanjing University: If other companies also want to invest, as long as they meet this condition, they can also participate, so more unwinning enterprises and unwinning varieties come in, which is equivalent to increasing supply
    .
    Both the number of varieties and the number of enterprises have increased, and through full competition, the price will also come down a little
    .
     
    The first procurement cycle of coronary stents is two years, officially landed from January 1, 2021, patients around the world have used high-quality and low-cost pharmaceutical products, and at present, the selected varieties with reduced prices have reached 1.
    69 million sets in clinical use, significantly reducing the burden
    of medical treatment for patients.
     
    On November 27, Liu Yefeng, a 40-year-old citizen of Changzhou, Jiangsu Province, was rushed to Changzhou First People's Hospital for treatment due to chest tightness, and was diagnosed
    with acute myocardial infarction by doctors.
    The doctor then performed interventional surgery on the patient and implanted 2 coronary stents
    .
    After the operation, the patient turned to safety, and when he heard that a coronary stent only cost 590 yuan, Liu Yefeng was surprised
    .
     
    As the "first order" of centralized procurement of high-value medical consumables organized by the state, the average price of the selected varieties was about 700 yuan, an average decrease of 93%, and related products landed in January 2021
    .
    During the first agreement period, medical institutions used a total of 1.
    69 million sets of selected coronary stents, reaching 1.
    6 times the annual agreed purchase volume, saving more than 17.
    9 billion yuan
    for the whole country.
    The affordability of percutaneous coronary intervention (PCI) surgery has been greatly improved, and according to relevant data, the volume of PCI surgery in China in 2021 increased by more than 40% compared with 2020, giving full play to the results of centralized procurement and effectively reducing the burden
    on the masses.
     
    Yang Xiaoyu, chief physician of the Department of Cardiology, Changzhou First People's Hospital of Jiangsu Province: We now have about 100 patients who need coronary intervention every month, and these patients are all using centralized stents, and we also communicate with suppliers in advance to equip them with different models of stents, with multiple brands to choose from, which can meet the clinical needs
    of patients.
     
    A total of 3,696 medical institutions participated, an increase of 1,288 compared with the first batch of centralized procurement, and a total of 1.
    865 million filled in demand, which was 1.
    7 times that of the first batch of centralized procurement, reflecting the high recognition
    of medical institutions for the centralized procurement policy.
     
    With the in-depth development of centralized procurement, more and more centralized procurement products will face the expiration of the procurement cycle.
    The continuous procurement of coronary stents also provides a reference
    for the renewal of other centralized procurement products.
     
    Since the establishment of the National Health Insurance Administration, 7 batches of centralized procurement of drugs have been carried out at the national level, and three batches of high-value medical consumables such as coronary stents and orthopedics have been carried out
    .
    Provincial and regional alliances have also been widely carried out in various places, and the selected products have significantly reduced the burden of patients' medical treatment
    .
    As local governments actively promote the centralized procurement of medical consumables, various places are facing the problem
    of product continuity.
     
    At present, the state has not issued a special policy document for the continuation of the national organization of medical consumables centralized procurement agreement after the expiration of the period, the national unified organization to carry out coronary stent continuation work can improve administrative efficiency, as far as possible to eliminate the situation of local non-standardization, inconsistency, reduce the cost of enterprise bidding around, can maximize the stability of the price level, coordinate the price difference between places, and ensure that all places are at the same price level.
    It also provides reference and reference significance
    for the development of follow-up work.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.